Chief Scientific Officer
United States of America
Dr. Maione has 22 years of experience in research, management and product development in the biotechnology industry. He has served as an officer at three companies that developed novel pharmaceutical products. Prior to joining Cytogel, Dr. Maione was the Chief Scientific Officer and Vice President of Research and Development at Seroptix. At Repligen, Dr. Maione held research and product development positions with responsibility for advancing novel therapeutic proteins and peptides from the lab into clinical development and also served as President and Chief Scientific Officer Repligen Development Corp. Dr. Maione previously also directed preclinical research for an amino acid prodrug that entered Phase III clinical trials for treatment of ARDS and SIRS at Transcend Therapeutics. Dr. Maione coordinates all Cytogel research and development efforts and has been instrumental in identifying Cytogel's primary products and creating its licensing and development strategy. Dr. Maione received a B.S. from Michigan State in 1978 and his Ph.D. from Cornell in 1983.